Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Receivables (2021 - 2023)

Historic Receivables for ADC Therapeutics (ADCT) over the last 3 years, with Q3 2023 value amounting to $21.2 million.

  • ADC Therapeutics' Receivables fell 890.71% to $21.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $21.2 million, marking a year-over-year decrease of 890.71%. This contributed to the annual value of $73.8 million for FY2022, which is 13793.34% up from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Receivables is $21.2 million, which was down 890.71% from $23.9 million recorded in Q2 2023.
  • ADC Therapeutics' Receivables' 5-year high stood at $73.8 million during Q4 2022, with a 5-year trough of $2079.0 in Q2 2021.
  • For the 3-year period, ADC Therapeutics' Receivables averaged around $21.8 million, with its median value being $22.2 million (2022).
  • As far as peak fluctuations go, ADC Therapeutics' Receivables soared by 100341130.35% in 2022, and later plummeted by 890.71% in 2023.
  • ADC Therapeutics' Receivables (Quarter) stood at $31.0 million in 2021, then soared by 137.93% to $73.8 million in 2022, then crashed by 71.29% to $21.2 million in 2023.
  • Its Receivables stands at $21.2 million for Q3 2023, versus $23.9 million for Q2 2023 and $24.0 million for Q1 2023.